NT-219

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameNT-219
Drug Alias NameNT-219NT219
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin receptor inhibitorsSignal transducer and activator of transcription 3 inhibitors
TargetsSignal transducer and activator of transcription 3Insulin receptor
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesTyrNovo Ltd
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Colorado DenverPurple Biotech LtdTyrNovo Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursHead and Neck NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A